Susceptibility genes for age-related maculopathy (ARM) on chromosome 10q26

• US 7,695,909 B2
• Filed: 06/07/2006
• Issued: 04/13/2010
• Est. Priority Date: 06/08/2005
• Status: Expired due to Fees

• Current Assignee: University of Pittsburgh of The Commonwealth System of Higher Education
• Original Assignee: University of Pittsburgh of The Commonwealth System of Higher Education
• Inventors: Ferrell, Robert E., Gorin, Michael B., Mah-Fraser, Tammy S., Weeks, Daniel E., Jakobsdottir, Johanna, Conley, Yvette P.
• Primary Examiner(s): BAUSCH, SARAE L
• Application Number:
  US11/448,267
• Publication Number:
  US 20060281120A1
• Time in Patent Office: 1,406 Days
• Field of Search: None
• US Class Current: 435/6.14
• CPC Class Codes: C12Q 1/6883 for diseases caused by alterations of genetic material
• CPC Class Codes: C12Q 2600/156 Polymorphic or mutational markers
• CPC Class Codes: C12Q 2600/172 Haplotypes

Abstract

Allelic variations in the genes PLEKHA1 and LOC387715 are identified herein as risk factor for Age Related Maculopathy (ARM). A method is therefore provided for identifying a risk of development of ARM in an individual that comprises identification of allelic variations in PLEKHA1 and/or LOC387715. Related apparatus, such as an array, are identified as being useful in implementing those methods.

Claims

1. A method of determining risk of developing Age-Related Maculopathy in a human subject comprising detecting the presence of a thymine or guanine at base 270 of SEQ ID NO:

20 (rs10490924) from a sample obtained from the subject, wherein the presence of thymine for one or both alleles indicates increased risk of developing Age-Related Maculopathy and the presence of guanine for both alleles indicates decreased risk of developing Age-Related Maculopathy.

2. The method of claim 1 comprising detecting the presence of a thymine or guanine base at rs10490924 in the LOC387715 gene.

3. The method of claim 1 further comprising examining allelic variation in one or more of PLEKHAI, PRSSII and LOC387715.

4. The method of claim 1 wherein the detecting step comprises examination of mRNA transcribed from LOC387715.

5. The method of claim 3 wherein the allelic variation is a mutation that produces one of a non-functional gene product and altered expression of a gene product.

6. The method of claim 3 wherein the allelic variation is one or more of a frameshift mutation, a promoter mutation and a splicing mutation.

7. The method of claim 1 further comprising detecting the presence in the subject of a polymorphism of complement factor H that indicates increased risk or decreased risk of developing Age-Related Maculopathy.

8. The method of claim 1 wherein the thymine or guanine is detected using a method comprising a nucleic acid amplification assay.

9. The method of claim 8 wherein the nucleic acid amplification assay comprises one of a PCR, a reverse transcriptase PCR (RT-PCR), an isothermic amplification, a nucleic acid sequence based amplification (NASBA), a 5′

fluorescence nuclease assay, a molecular beacon assay and a rolling circle amplification.

10. The method of claim 1 wherein the thymine or guanine is detected using an array.

11. The method of claim 1 wherein the Age-Related Maculopathy is Age-related Macular Degeneration.

12. A method of determining risk of developing Age-Related Maculopathy in a human subject comprising identifying an allelic variant isoform of the gene product of LOC387715, wherein said allelic variant isoform is either Ser or Ala at position 69 of LOC387715, wherein the presence of Ser indicates increased risk of developing Age-Related Maculopathy and the presence of Ala indicates decreased risk of developing Age-Related Maculopathy.